KIMBERLY A. MARTIN
M.D., FRCSC, FCCMG, FACOG, FACMG, Medical Director for Reproductive Testing, Natera
Dr. Martin received her medical degree from McGill University, Montreal,Canada. She completed her residency in Obstetrics and Gynecology at the University of Western Ontario, London, Canada and a fellowship in Clinical Genetics at the University of British Columbia, Vancouver, Canada. She is board certified in both Obstetrics and Gynecology and Clinical Genetics in Canada and the United States. Her clinical experience in prenatal diagnosis, ultrasound, and genetic counseling spans over 20 years in both academic and community-based healthcare settings and she has participated in the training of medical students, residents and fellows in maternal-fetal medicine. She has lectured extensively about reproductive genetics and is particularly interested in the education of providers/patients and medical ethics. Dr. Martin is the Medical Director for Reproductive Testing for Natera, a biotechnology company that has developed the SNP based approach to noninvasive screening.
Session: Expansion of Non-Invasive Prenatal Testing
Noninvasive prenatal testing (NIPT) or screening (NIPS) has been widely adopted and its use no longer questioned in high risk settings. However, over the past year, further research and payor models have demonstrated the utility of extending NIPT to the average risk population potentially impacting approximately 5,000,000 pregnancies per year. This session will review the data on NIPT performance in the average risk population, as well as provide clinical and reimbursement perspective.